Evotec OAI achieves milestone with Vertex Pharmaceuticals
Evotec OAI, of Germany, has achieved a clinical milestone in its drug discovery chemistry services agreement with global biotechnology company Vertex Pharmaceuticals.
Evotec OAI, of Germany, has achieved a clinical milestone in its drug discovery chemistry services agreement with global biotechnology company Vertex Pharmaceuticals.
An undisclosed milestone payment has been triggered by a drug candidate advancing in clinical testing. This drug candidate was identified and optimised with the help of chemistry services and libraries provided to Vertex by Evotec OAI.
As part of an agreement that began in 1998, Vertex has utilised a broad range of Evotec OAI's chemistries, while Evotec OAI has provided compounds and compound arrays for pharmaceutical screening and lead optimisation. 'We are proud to have significantly contributed to the optimisation of one of Vertex's clinical candidates,' said Joern Aldag, president and ceo of Evotec OAI. 'The achievement of this clinical milestone is a true validation of the quality of our chemistry support.'